Advancing an inspired pipeline of novel IL-1β therapies focused on treating unmet medical needs.
Avalo announces positive top line data from LOTUS study in moderate to severe Hidradenitis Suppurativa (HS)Press releasepresentation
Avalo is a clinical-stage biotechnology company
fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases. Positive topline data was recently reported for our lead asset, abdakibart (AVTX-009), in a Phase 2 trial in hidradenitis suppurativa (HS). We’re also exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs.
Developing new medicines targeting the IL-1β pathway
Discover our innovative approach to next-generation treatments for inflammation.
